Capivasertib

Generic Name: Capivasertib

Brand Names: Truqap

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅ClN_₆O_₂

CAS Number: 1143532-39-1

Unique Ingredient Identifier: WFR23M21IE

Background: Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.

Clinical Trials

mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian

Phase 1

Active, not recruiting

Conditions: Progesterone Receptor Negative
Stage III Uterine Corpus Cancer AJCC v7
Stage IV Uterine Corpus Cancer AJCC v7
Triple-Negative Breast Carcinoma
BRCA2 Mutation Carrier
High Grade Ovarian Serous Adenocarcinoma
Recurrent Fallopian Tube Carcinoma
BRCA1 Mutation Carrier
Recurrent Ovarian Carcinoma
Recurrent Uterine Corpus Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Capivasertib
Other: Pharmacological Study
Drug: Olaparib
Drug: Vistusertib

First Posted Date: 2014-08-05

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 159

Registration Number: NCT02208375

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: AZD5363
Drug: Placebo

First Posted Date: 2014-04-23

Last Posted Date: 2022-05-05

Lead Sponsor: University Hospital Southampton NHS Foundation Trust

Target Recruit Count: 160

Registration Number: NCT02121639

Locations: 🇬🇧
Southampton General Hospital, Southampton, Hampshire, United Kingdom

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Standard maintenance for squamous NSCLC
Drug: AZD2014
Drug: Durvalumab
Drug: AZD4547
Drug: Pemetrexed
Drug: AZD5363
Drug: AZD8931
Drug: Selumetinib
Drug: Vandetanib
Drug: savolitinib
Drug: Olaparib

First Posted Date: 2014-04-17

Last Posted Date: 2024-01-10

Lead Sponsor: UNICANCER

Target Recruit Count: 999

Registration Number: NCT02117167

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

and more 34 locations

AKT Inhibitor in Oestrogen Positive Breast Cancer

Phase 2

Completed

Conditions: Invasive Breast Cancer

Interventions: Drug: AZD5363

First Posted Date: 2014-03-04

Last Posted Date: 2017-05-04

Lead Sponsor: University of Nottingham

Target Recruit Count: 48

Registration Number: NCT02077569

Locations: 🇬🇧
Royal Derby Hospital, Derby, Derbyshire, United Kingdom
🇬🇧
Kingsmill Hospital, Sutton-in-Ashfield, Nottinghamshire, United Kingdom
🇬🇧
Plymouth Hospitals NHS Trust, Derriford, Plymouth, Devon, United Kingdom

and more 8 locations

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Phase 1

Conditions: Estrogen Receptor Positive Breast Cancer

Interventions: Drug: Placebo
Drug: AZD5363
Drug: Fulvestrant

First Posted Date: 2013-11-25

Last Posted Date: 2022-08-10

Lead Sponsor: Velindre NHS Trust

Target Recruit Count: 149

Registration Number: NCT01992952

Locations: 🇬🇧
Royal Blackburn Hospital, Blackburn, United Kingdom
🇬🇧
Christie Hospital, Manchester, Greater Manchester, United Kingdom
🇬🇧
Ysbyty Gwynedd, Bangor, United Kingdom

and more 18 locations

Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability

Phase 1

Completed

Conditions: Advanced Solid Malignancy,
Safety and Tolerability,
Pharmacokinetics, Pharmacodynamics,
Tumour Response,

Interventions: Drug: AZD5363

First Posted Date: 2013-07-11

Last Posted Date: 2016-05-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 33

Registration Number: NCT01895946

Locations: 🇬🇧
Research Site, Surrey, United Kingdom

Open Label Phase 1 Study in Japan for Patient With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Advanced Solid Malignancy
Advanced Solid Tumor

Interventions: Drug: AZD5363

First Posted Date: 2011-05-16

Last Posted Date: 2016-04-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 39

Registration Number: NCT01353781

Locations: 🇯🇵
Research Site, Chuo-ku, Japan

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Phase 1

Completed

Conditions: Advanced Solid Malignancy
Pharmacokinetics
Tumour Response
Safety and Tolerability
Advanced or Metastatic Breast Cancer
PTEN
ER Positive
Ovarian Cancer
PIK3CA
AKT1

Interventions: Drug: AZD5363

First Posted Date: 2010-10-22

Last Posted Date: 2024-12-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 285

Registration Number: NCT01226316

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy